Actively Recruiting
Study of Repetitive Transcranial Magnetic Stimulation rTMS to Treat Apathy in Alzheimers and Other Neurocognitive Disorders With or Without Methylphenidate Medication
Led by Sunnybrook Health Sciences Centre · Updated on 2026-04-13
10
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Apathy, characterized by lack of interest and enthusiasm, is a common and disabling early symptom in conditions like Alzheimers disease, dementia, mild behavioural impairment, and other neurocognitive disorders. Researchers are evaluating repetitive transcranial magnetic stimulation rTMS, a non-invasive brain stimulation, as a treatment for apathy in people with these conditions. The study also examines rTMS effects in individuals both receiving and not receiving methylphenidate, a medication previously shown to improve apathy. Participants receive one of two treatments rTMS combined with methylphenidate or rTMS alone. Both treatments are being studied to understand their impact on apathy symptoms. This is a non-randomized, single-masked study where participants are assigned to either treatment group. The trial began in February 2023 and is sponsored by Sunnybrook Health Sciences Centre. During the trial, researchers assess apathy using the Neuropsychiatric Inventory-apathy scale after 2 weeks. Care partners who spend significant time with participants will be involved. Participants must have stable medication doses related to cognition or behavior for at least 4 weeks prior. Safety monitoring excludes people with certain medical conditions or current depressive episodes. The study will continue until December 2026.
CONDITIONS
Brief Title
rTMS for Apathy Clinical Trial
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here